SEPRACOR'S LUNESTA STUDY RESULTS PRESENTED

Sepracor presented results from its second six-month, Phase IIIB/IV study of Lunesta brand eszopiclone in adult patients with chronic insomnia at the American Neurological Association annual meeting in San Diego.

The long-term, 828-patient, randomized, double-blind, placebo-controlled study evaluating safety and efficacy of Lunesta also included a two-week discontinuation phase in which all patients were administered placebo. This study is the second long-term, six-month, double-blind, placebo-controlled study of Lunesta in patients suffering from chronic insomnia. The results of this study augment the findings of the first six-month study, which was published in the journal SLEEP in November 2003.